Physician profile

George Grunberger

Endocrinology, Diabetes & Metabolism · Bloomfield Hills, MI

NPI 1477558450

$930,769.46

in general payments reported to CMS, 2019-2025

67 companies · $139K in 2025

The $139K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$234,438.23
Consulting Fee$37,052.50
Travel and Lodging$28,198.05
Food and Beverage$15,461.70
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program$10,618.75
Honoraria$9,124.60
Education$45.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $452,232.57 2019-2025 Mounjaro, Zepbound, Jardiance
Novo Nordisk INC $113,077.49 2019-2025 Ozempic, Wegovy, Rybelsus
Abbott Laboratories $76,867.91 2019-2025 Freestyle Libre 3, Freestyle Libre, Freestyle Libre Pro
Sanofi-Aventis U.S. LLC $69,787.63 2019-2025
Nevro Corp. $45,320.97 2021-2024 Senza
Lifescan, INC. $21,101.84 2020-2023
Mannkind Corporation $15,512.22 2019-2025 Afrezza
Cequr Corporation $14,552.26 2022-2025 Cequr Simplicity
Vertex Pharmaceuticals Incorporated $13,097.56 2023-2025
Astrazeneca Pharmaceuticals Lp $10,139.93 2019-2022
Senseonics, Incorporated $10,136.00 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $9,906.93 2019-2025 Jardiance, Synjardy, Tradjenta
Xeris Pharmaceuticals, INC. $9,634.62 2020-2025 Gvoke Hypopen
Janssen Pharmaceuticals, INC $9,160.74 2019-2022
Ipsen Bioscience INC. $8,977.50 2023
Show all 66 companies
CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Rcv Gmbh & Co Kg $7,745.98 2019-2022
Tandem Diabetes Care, INC. $5,883.84 2019-2024 T:Slim X2 Insulin Pump With Control-Iq
Amarin Pharma, INC. $5,819.66 2019-2022
Dexcom, INC. $4,726.74 2020-2025 Dexcom G6 Transmitter
Medtronic, INC. $4,247.64 2021-2025 Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System
Lexicon Pharmaceuticals, INC. $3,949.37 2019-2025 Inpefa
Corcept Therapeutics $3,530.90 2019-2025 Korlym
Valeritas, INC. $3,342.34 2019
Becton, Dickinson and Company $3,088.12 2019-2022
Eli Lilly and Company $2,625.00 2019-2020
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $1,504.74 2019-2020
Merck Sharp & Dohme LLC $1,341.98 2019-2020
Esperion Therapeutics, INC. $355.73 2021-2025 Nexletol
Amgen INC. $350.51 2022-2025 Evenity, Tepezza, Prolia
Radius Health, INC. $251.93 2022-2025 Tymlos
Bayer Healthcare Pharmaceuticals INC. $233.09 2022-2025
Sequel Med Tech, LLC $217.84 2025 Twiist
Beta Bionics, INC. $154.85 2023-2025 Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach
Antares Pharma, INC. $145.99 2021-2023 Tlando, Xyosted, Nocdurna
Clarus Therapeutics INC. $137.44 2021
Insulet Corporation $120.38 2019-2024 Omnipod
Medtronic Minimed, INC. $115.11 2019-2020
Ascendis Pharma Endocrinology INC $102.40 2023
Ascensia Diabetes Care US INC. $91.30 2024-2025
Amneal Pharmaceuticals LLC $88.34 2022-2024 Unithroid
Recordati_rare_diseases_inc. $81.94 2020-2024 Isturisa, Signifor Lar
Ipsen Biopharmaceuticals, INC $79.80 2020-2022
Embecta Corp. $71.97 2023 Bd Nano 2nd Gen Pen Needle
Madrigal Pharmaceuticals $70.43 2025 Rezdiffra
Takeda Pharmaceuticals U.S.A., INC. $62.24 2021
Amryt Pharma Holdings Ltd $57.93 2022
Amphastar Pharmaceuticals, INC. $56.05 2024-2025
Vivus LLC $55.87 2020-2021
Alexion Pharmaceuticals, INC. $48.97 2023 Strensiq
Janssen Scientific Affairs, LLC $48.63 2019
Abbvie INC. $46.41 2020-2021
Ultragenyx Pharmaceutical INC. $45.56 2023-2024 Crysvita
Kyowa Kirin, INC. $44.07 2025
Companion Medical, INC. $43.34 2019-2020
Zimmer Biomet Holdings, INC. $37.48 2021
Horizon Therapeutics Plc $33.96 2020-2022
Chiesi USA, INC. $33.66 2024-2025 Mycapssa
Averitas Pharma INC. $28.14 2023 Qutenza
Neurocrine Biosciences, INC. $26.75 2024 Crenessity
Novartis Pharmaceuticals Corporation $22.50 2022
Alvogen INC $22.20 2024 Teriparatide
Eusa Pharma (US) LLC $19.99 2022
Grt US Holding, INC. $14.56 2022
Kowa Pharmaceuticals America, INC. $13.78 2021
Alfasigma USA, INC. $13.21 2021
Eisai INC. $12.63 2019

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$13,711.34 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

George Grunberger

$930,769.46

in general payments reported 2019-2025

Years
2019-2025
Top company
Lilly USA, LLC
Context
The $139K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).

https://glasscript.com/doctor/293935/george-grunberger

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.